| Outcome Measures: |
Primary: Number of Treatment Emergent Adverse Events(TEAEs), through study completion, an maximum of 8 weeks | Secondary: Number of Nausea and vomiting during titration, through study completion, an maximum of 8 weeks|Mean Change From Baseline in Body Weight at different dose steps, through study completion, an maximum of 8 weeks|Change in plasma concentration of HS-20004 from baseline at different dose steps, through study completion, an maximum of 8 weeks|Change in plasma concentration of glucose from baseline at different dose steps, through study completion, an maximum of 8 weeks|Change in plasma concentration of insulin from baseline at different dose steps, through study completion, an maximum of 8 weeks|Change in plasma concentration of glucagon from baseline at different dose steps, through study completion, an maximum of 8 weeks|The minimum dose of HS-20004 that could keep plasma glucose under 6.1 mmol/L in Type 2 Diabetic Patients, through study completion, an maximum of 8 weeks
|
